These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847 [TBL] [Abstract][Full Text] [Related]
4. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863 [TBL] [Abstract][Full Text] [Related]
5. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
6. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833 [TBL] [Abstract][Full Text] [Related]
7. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. Jerónimo C; Usadel H; Henrique R; Oliveira J; Lopes C; Nelson WG; Sidransky D J Natl Cancer Inst; 2001 Nov; 93(22):1747-52. PubMed ID: 11717336 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. Trock BJ; Brotzman MJ; Mangold LA; Bigley JW; Epstein JI; McLeod D; Klein EA; Jones JS; Wang S; McAskill T; Mehrotra J; Raghavan B; Partin AW BJU Int; 2012 Jul; 110(1):56-62. PubMed ID: 22077694 [TBL] [Abstract][Full Text] [Related]
9. A quantitative promoter methylation profile of prostate cancer. Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627 [TBL] [Abstract][Full Text] [Related]
10. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. Harden SV; Sanderson H; Goodman SN; Partin AA; Walsh PC; Epstein JI; Sidransky D J Natl Cancer Inst; 2003 Nov; 95(21):1634-7. PubMed ID: 14600096 [TBL] [Abstract][Full Text] [Related]
11. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. King CR; McNeal JE; Gill H; Presti JC Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152 [TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Bernardini S; Miano R; Iori R; Finazzi-Agrò E; Palmieri G; Ballerini S; Angeloni C; Orlandi A; Bellincampi L; Cortese C; Federici G Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706 [TBL] [Abstract][Full Text] [Related]
14. Multigene methylation analysis for detection and staging of prostate cancer. Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436 [TBL] [Abstract][Full Text] [Related]
15. Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer. Hashad DI; Hashad MM; Talaat IM; Ibrahim MA Genet Test Mol Biomarkers; 2011 Oct; 15(10):667-70. PubMed ID: 21631298 [TBL] [Abstract][Full Text] [Related]
16. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653 [TBL] [Abstract][Full Text] [Related]
17. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. Epstein JI; Walsh PC; Akingba G; Carter HB J Urol; 1999 Nov; 162(5):1649-52. PubMed ID: 10524890 [TBL] [Abstract][Full Text] [Related]
18. Needle biopsy findings in prostatic adenocarcinoma: experience at a tertiary care center in a developing country. Ahmad Z; Arshad H Ann Diagn Pathol; 2013 Jun; 17(3):235-8. PubMed ID: 23199761 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. Stewart GD; Van Neste L; Delvenne P; Delrée P; Delga A; McNeill SA; O'Donnell M; Clark J; Van Criekinge W; Bigley J; Harrison DJ J Urol; 2013 Mar; 189(3):1110-6. PubMed ID: 22999998 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Crocitto LE; Korns D; Kretzner L; Shevchuk T; Blair SL; Wilson TG; Ramin SA; Kawachi MH; Smith SS Urology; 2004 Oct; 64(4):821-5. PubMed ID: 15491741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]